Namita Khanna

Namita is a successful senior-level business leader driving more than two decades of exceptional results focused on sales, business development, and account management across diverse markets including healthcare, finance, and hospitality. She is strategic and multidisciplinary with an eye for innovation, positioning, and relevance. She has worked for a wide array of Fortune 500 firms such as American Express, Marriott International, and Eli Lilly and Company.

Namita began her career in the Northeast. She attended Widener University in Philadelphia obtaining an undergraduate degree in Hospitality Management. Following an international feasibility project in Asia, she was chosen for the Marriott Executive Sales Training Program working in New York and the Washington DC area. After moving to Northern Virginia, Namita then returned to school to continue her education in Finance and Investments receiving her Series 6,7, 63, 65, and all relevant financial licenses to begin working as a Financial Investment Advisor with American Express in DC and then Atlanta. In 1997, after working in a successful group practice in Atlanta, she transitioned to the Pharmaceutical Industry and worked in hospitals and institutions for 17 years from New Jersey to Atlanta, to Orlando for Eli Lilly and Company. After a short three-year period with an acute care hospital-based company named The Medicines Company, Namita created her own consulting firm and continued working in Orlando, Florida. She is currently working with her third start-up company and is Vice President of Strategic Development for Vero Biotech, an early-stage biotech company located in Atlanta, Georgia. She was intimately involved in the first commercial launch for the company and specializes in Communications and Marketing at Vero. She is currently focused on the development of the company and its ground-breaking innovations. Namita has a special interest in how successful people and companies communicate, and is focusing on strategies involving how to bring innovation to medicine.